next-gen GLP-1 mechanisms and one of them is like reverse tirzepatide
A comprehensive review of next-generation GLP-1 therapies highlighted that both GIP receptor agonism and antagonism in combination with GLP-1 receptor agonism have shown promise. Maridebart cafraglutide combines GLP-1 receptor agonism with GIP receptor antagonism, the opposite approach to tirzepatide which activates GIP, yet both approaches appear to enhance weight loss outcomes through different mechanisms.
Tirzepatide activates GIP and gets superior results. A different drug blocks GIP alongside GLP-1 and also gets superior results. The same receptor, activated vs blocked, both producing better weight loss than GLP-1 alone. That suggests GIP's role in metabolism is far more complex than the current framing captures and that we are still genuinely early in understanding why any of this works.